The complications associated with conjunctival flaps
typically are mild and clinically minor, and typically occur
due to inadequate surgical technique (9-11). However,
the flap historically had higher complication rates up to
24% (12). The complications include enlargement of flap
buttonholes, flap retraction, epithelial cysts around the
limbus, ptosis, erosion from underlying ulcer (rare), and
persistence of pain (rare) when flap is contraindicated (e.g.,
absolute glaucoma or phthisis) but still used instead of
enucleation (9).
Hemorrhage
Hemorrhage under the flap can occur within the
first postoperative week, which can decrease the flap
transparency (9).
Flap retraction
Poor surgical mobilization and adherence of the flap can
lead to flap retraction. However, flap retractions occur
infrequently and can be revised surgically (11).
Buttonhole formation
In addition, buttonholes in the flap can occur when
separating Tenons capsule from the overlying conjunctiva.
Buttonhole formation can be minimized by the help of
an assistant to hold up the edges of the conjunctiva while
performing the dissection with blunt tipped scissors.
Buttonholes can lead to further ulceration in the area and
should be closed using 10-0 nylon sutures incorporating
the flap into the surrounding corneal tissue. Meticulous
suturing technique is important. The buttonhole
enlargement may be clinically insignificant in the absence
of underlying inflammatory corneal disease or traction of
the flap. A buttonhole will enlarge regardless of its size
intraoperatively. Traction can lead to not only buttonholes
but also retraction and tearing of the conjunctival flap from
the sutures. A buttonhole with underlying inflammatory
corneal disease may be mistaken for flap erosion.
Buttonholes and flap erosions are difficult to treat; they
frequently require a new conjunctival flap made from
undisturbed conjunctiva (9). If a small hole is formed in the
flap by accident, it can be sutured with satisfactory results
with 10-0 or 11-0 nylon on an atraumatic needle like those
used in microvascular surgery (13). An extra flap from the
inferior bulbar conjunctiva may be used if the defect is
significant.
Cyst formation
Incomplete removal of corneal epithelium may result in
epithelial inclusion cysts, which are often occur at the
limbus. Small epithelial inclusion cysts have been reported
to occur at a rate of 2.5% (11). The cysts may be easily
drained with a needle but often recur; excision of the cyst
wall can prevent such recurrence (9,11).
Fluid accumulation under flap
Fluid collection may occur under the flap if perforation
occurs either during or before the procedure is performed.
Among 122 cases, none had fluid accumulation between the
cornea and flap (9), in comparison to Gundersen’s report in
1969 (14).
Ptosis
Postoperative ocular discomfort often results in ptosis,
which usually resolves along with the discomfort. However,
a complication of longstanding ptosis may develop from the
excision of excessive conjunctival tissue from the superior
fornix, thus exerting downward traction of the lid (9). The
incidence of mild ptosis has been reported as high as 7%
but can be avoided by leaving a symblepharon shell in
place for 4 weeks to prevent superior fornix scarring and
foreshortening (11).
Persistent pain
There have been very few cases with mild, persistent
discomfort or photophobia postoperatively. Persistent
pain is a rare complication that typically occurs only when
a conjunctival flap is not the proper treatment, such as in
phthisis bulbi or absolute glaucoma (9).
Flap melt
The most serious complications are flap melt and corneal
perforation, which have been reported in 1.2% of the cases,
typically 2 to 4 weeks after the procedure (13).
Reported series and success rates
Conjunctival flaps have been used for numerous and varied
corneal conditions, with success characterized as globe
preservation, prevention of endophthalmitis, in addition
to decreased pain, fewer required follow up visits, and less
frequent topical medications.
Gundersen and Pearlson’s review of corneal cases over
thirty-seven years showed the greatest utility of conjunctival
flaps in treating chronic herpetic keratitis and impending
perforations. They found value in treating neuroparalytic
keratopathy, marginal ulceration, severe endocrine
exophthalmos, filamentary keratopathy, and other obstinate
corneal disease. The most common indication was bullous
keratopathy (14), which no longer requires such treatment
because of the development of advanced transplantation
techniques, such as Descemet’s stripping automated
endothelial keratoplasty and Descemet’s membrane
endothelial keratoplasty.
Paton and Milauskas reported the benefits of relief of
symptoms, therapeutic benefits, and cosmetic improvement
in their reviewed of 122 consecutive cases. Contrary
to Gunderson, they did not advocate keratectomy and
only recommended removing necrotic tissue and surface
epithelium. Many of their cases were corneal ulcers resistant
to therapy, including viral, bacterial, and fungal infections. They reported two failed cases associated with Mooren’s
ulcer, in which the flap did not halt the disease process (9).
This failure in treating Mooren’s ulcers was confirmed by
Li et al. in 2017 (15).
For eyes with treatment-resistant corneal conditions,
the Gundersen flap has successfully provided a stable
ocular surface, with resolution of the symptoms and
no flap retractions or dehiscence (12). In 33 cases of
treatment-resistant corneal disease, half of which had
bacterial or viral ulcers, 25 received a total hood flap and
eight a partial conjunctival flap. One third of the cases
had undergone prior penetrating keratoplasty (PKP) and
received conjunctival flaps when the grafts completely
failed. Overall, 9 of the thirty-three underwent PKP an
average of 14.8 months following the flap procedure, with
improvement of visual acuity in eight of these patients (16).
A partial or total flap successfully stabilizes the patient’s
ocular surface in most cases despite the risk of postoperative
flap recession and the need for surgical intervention.
Conjunctival flap surgery is an important and useful
surgical option in the treatment of ocular surface disease,
especially for recalcitrant infectious keratitis and corneal
ulcers (17). For refractory corneal defects, conjunctival
flaps provide liberation from pain, intensive surface
treatment, and frequent examinations. Conjunctival flaps,
though rarely applied, present the best treatment for
refractory neurotrophic keratitis and non-healing epithelial
defects (13).
Conjunctival flaps also provide prompt
resolution of ulceration in neurotrophic corneal disease (18).
Conjunctival flaps in the treatment of herpes keratouveitis
with persistent corneal epithelial defects resulted in intact,
healthy ocular surface and a non-inflamed eye require few
medications and infrequent office visits. No patients had
recurrent live viral activity. The surgical techniques for these
cases varied; Tenons capsule was not completely removed
from the conjunctiva, but instead, about one-third thickness
of Tenons was included with the flap (19).
Alino and Perry concluded that conjunctival flaps were
underutilized and should be considered for persistent non-healing epithelial defects, based on their five-year review
of 61 patients, with 48 total and 13 partial conjunctival
flaps (20). The 7 complications included two flap retractions
that required re-suturing in the total flap group, as well as
three flap retractions in the partial flap group. One case
that received a partial flap required a conversion to total
flap with lamellar keratoplasty one week postoperatively,
followed by flap retraction with subsequent corneal
perforation four months postoperatively that required PKP and tarsorrhaphy. An additional patient with a partial
conjunctival flap suffered perforation after flap retraction,
requiring PKP.
The modified selective pedunculated superior forniceal
conjunctival flap provides successful globe preservation for
non-healing, non-traumatic corneal melts and perforations,
including those secondary to bacterial keratitis,
neurotrophic keratitis, and multiple retinal procedures
with previous corneal grafts with compromised ocular
surfaces. This surgical technique is appropriate in the
managing impending and frank corneal perforations when
donor material is not available and tissue transplantation in
unsuitable (7).
In 2013, a novel approach using fibrin glue for
Gundersen flap surgery reduced surgical procedure time,
hastened ocular surface rehabilitation, and had similar
outcomes to conventional conjunctival flap surgery. Seven
of seven patients achieved a stable ocular surface with
no flap retractions or exposure of the underlying corneal
surface (21).
A 10-year 2017 review of 251 eyes in 253 patients showed
success of flaps in maintaining globe integrity; reducing pain
and the inflammatory process; arresting corneal ulceration;
and preventing secondary infections. The flap acts as a
biologic patch with trophic, protective, and analgesic
effects, thus controlling local corneal infections, melts, and
perforations to preserve the globe. Clinically, 224 patients
(88.5%) had vision no worse than preoperatively, though
a best-corrected visual acuity (BCVA) of 29 (11.5%) of the
patients decreased postoperatively (13).
Disadvantages
Vision may be impaired in circumstances where the flap
covers the visual axis. Visual acuity may be preserved in
cases where the flap only covers the peripheral cornea.
However, in most cases where a whole conjunctival flap
is required, the globe’s integrity, rather than vision, is the
primary issue.
Conjunctiva covering the entire cornea inhibits
monitoring of disease progression by preventing any view of
the anterior chamber and prevents direct view of the corneal
pathology. Unless the flap is very thin or very peripheral,
the cosmetic aspect may be an issue for the patient, and this
should be discussed with the patient before surgery.
Conjunctival flaps render the monitoring of glaucoma
difficult, due to the inability to accurately measure
intraocular pressure (6). The significant conjunctival dissection and mobilization that occurs during the
Gundersen flap technique jeopardizes the donor site if the
patient has a trabeculectomy in the future (7).
While local retrobulbar injection and, in some cases,
local infiltration anesthesia can be used to perform this
procedure, it is still a surgical procedure that requires the
patient to undergo significant surgical manipulation and
should only be considered after non-surgical options have
been exhausted.
Alternative treatments
The number of cases requiring conjunctival flap cover
surgery has decreased over time. This could be attributed to
the availability of alternate and more effective treatments for
significant ocular surface problems, such as tissue adhesives,
soft bandage contact lenses, more powerful antimicrobials,
better ocular lubrication systems, immunosuppressive drugs,
and other surgical procedures are used.
Conservative medical techniques in the care of non-healing corneal ulcerations and impending perforations vary
in their success, depending on the extent and etiology of
the disease process. Punctal plugs and punctal cautery can
relieve dry eyes, and bandage contact lenses are sometimes
helpful. In addition, tarsorrhaphy may be required
if lagophthalmos is due to mechanical or neurologic
causes, while botulinum toxin injections into the levator
can provide ptotic protection. Autologous serum tears
containing neurotrophic growth factors can help promote
epithelial cell proliferation, migration, and differentiation.
Oral tetracycline reduces inflammatory mediators and have
been reported to improve healing of epithelial defect by
inhibiting bacterial lipases and lipid peroxidases.
Amniotic membrane grafts can help promote healing
in the slowly healing corneal ulcer. Acting as a basement
membrane, these tissues are believed to guide and promote
epithelial proliferation and migration while supporting cell
adhesion. They are also believed to inhibit inflammation
and corneal necrosis, as the amniotic membrane stroma
contains proteinase inhibitors. Newer therapies, such as the
nerve growth factor Oxervate [cenegermin, recombinant
human nerve growth factor (rhNGF); Boston, MA:
Dompé U.S. Inc.], provide a promising approach to the
treatment of persistent corneal epithelial defects, but are
often insufficient in maintaining ocular surface stability in
extreme cases.
Corneal neurotization has proved successful in some cases
of neurotrophic keratopathy. Various techniques using direct
nerve transfer of the ipsilateral infraorbital, supraorbital, or
supratrochlear nerves have been developed, in addition to
processed nerve allografts. Confocal microscopy has shown
re-innervation in as early as six months. Limitations of these
alternative treatments also exist, however. Corneal donor
tissue may not be available for patch grafting, lamellar, or
full-thickness transplantation. Necrotic, inflamed tissue in
the peripheral cornea may also impair the ability to perform
a PKP. The amniotic membrane and umbilical cord grafting
are limited in that they may not provide a robust enough
substitute for healing compared to the properly prepared
vascularized conjunctival flap. Using transplant materials
always carries the risk of infectious or prion disease
transmission. ProKera may fail to succeed in enhancing
corneal epithelial cell proliferation and inhibiting stromal
tissue loss and ulceration. Bandage contact lenses, such as
Kontur (Hercules, CA: Kontur Kontact Lens, Co., Inc.),
still require medications and frequent office visits and
medical monitoring, while still presenting an increased risk
of microbial keratitis.
Optical rehabilitation after conjunctival flap
Conjunctival flaps may be performed to preserve and
stabilize the globe for a cosmetic scleral shell or for future
sight-restoring surgery. Patients can also be fitted with an
iris-print contact lens as early as 4–6 weeks postoperatively
for cosmesis (11).
One advantage of the conjunctival flap is that it can
be removed easily for additional vision restoring surgery.
Removal requires only a minor surgical procedure; topical
anesthesia is sufficient, but retrobulbar anesthesia is
preferable. In cases where Bowman’s membrane is intact,
such as bullous keratopathy, the flap can be nicked and
peeled off the cornea (to at least 1 mm peripheral to the
limbus to avoid regrowth of the flap onto the cornea).
Especially in cases of peripheral corneal disease, a trephine
placed over the flap can be used to protect the peripheral
cornea while the central button of flap tissue is excised
with scissors and fine-tipped forceps. As ingrowth of the
flap tends to reduce the size of the central window, a large
trephine (e.g., 9 mm) should be implemented. Indications
for flap excision were vision improvement in cases of
peripheral corneal scarring, examination of the cornea for
future PKP, and cosmesis after resolution of inflammatory
processes (9).
If the goal of flap removal is to improve visual acuity,
corneal surgery is usually required. PKP should never be carried out simultaneously with the removal of the
flap; it should only be considered after a few weeks until
inflammation recedes, and the cornea heals. Furthermore,
if additional corneal surgery is performed soon after flap
excision, conjunctival tissue tends to regenerate onto the
peripheral cornea. In cases of herpetic keratitis, a period of
at least 8 months before flap removal is not always necessary
but allows for maximum corneal healing and prevention
of recurrence of chronic herpetic keratitis (9). Insler and
Pechous performed nine PKPs in patients with flaps. Vision
improved in eight cases. It was concluded that total and
partial therapeutic conjunctival flaps improved the recipient
bed and facilitated a successful result following PKP in
severely inflamed eyes (12).
Removal of the conjunctival flap is not necessary before
a corneal graft surgery; keratoplasty with the conjunctival
flap remaining has resulted in similar benefits and few
complications and also requires no change in keratoplasty
technique (22).
The selection of cases for PKP after conjunctival flaps
should be limited to those without other sight-threatening
comorbidities, such as uveitis, glaucoma, cataracts, and
diseases of the optic nerve and retina. Conjunctival flaps
have shown to improve the condition of the recipient bed
for transplant in severely inflamed eyes. The therapeutic
conjunctival graft serves to mitigate the advanced
inflammation, vascularization, corneal ulceration, and
substantial risk for transplantation, thus increasing the
possibility for a successful corneal graft. Histopathologic
study of the buttons showed that the surface conjunctival
epithelium thickened with increased goblet cells, with
underlying conjunctival chorion and corneal stromal
collagen lamellae. Reported complications include graft
rejection and glaucoma that were all treated medically (20).
Advantages of various techniques
In comparison to the Gundersen and partial flaps, the
selective pedunculated conjunctival flap and SFCAP
neither require extensive conjunctival dissection nor
obscure the whole cornea. This allows postoperative
observation of the anterior chamber. The SFCAP and the
pedunculated flap with Tenon’s capsule also provide enough
thickness to successfully treat impending or frank corneal
perforations (6,7,22).
Summary
Conjunctival flaps have historically demonstrated success
in preserving the globe in patients with severe ocular
surface disease. There are multiple indications for their
use, including infectious keratitis, neurotrophic keratitis,
nontraumatic corneal melts, descemetoceles, perforations,
and corneal burns. The flaps provide nutritional, metabolic,
structural, and vascular support, while limiting inflammation
and infection. The extraocular surgical techniques can be
performed in various ways, including bipedicle (superior
or inferior), partial or total, as well as pedunculated. Fewer
flaps are performed today because of the development of
other treatment modalities, including serum tears, bandage
lenses, corneal grafting (both lamellar and full thickness),
Oxervate, amniotic membrane, and umbilical cord grafting.
Despite the availability of newer conservative medical
modalities, conjunctival flaps have proven successful and
beneficial in various ways that these alternatives have not.
Conjunctival flaps can prevent the emotional and
psychological effects of enucleation or evisceration. while
decreasing pain, discomfort, and inflammation. Moreover,
patients need fewer medications and office visits, while
retaining the future option for visual rehabilitation when
appropriate. The future will likely present us with new
technologies and techniques for globe preservation and
sight restoration. The conjunctival flap may serve as an
intermediate step towards the integration of these novel
modalities. Currently, this procedure remains a viable and
important instrument in our surgical toolbox.